Current Applications and Future Perspectives of CRISPR-Cas9 for the Treatment of Lung Cancer

Markeshaw Tiruneh G/Medhin,1 Endeshaw Chekol Abebe,2 Tekeba Sisay,3 Nega Berhane,3 Tesfahun Bekele Snr,1 Tadesse Asmamaw Dejenie1 1Department of Biochemistry, School of Medicine, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia; 2Department of Biochemistry, College of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tiruneh G/Medhin M, Chekol Abebe E, Sisay T, Berhane N, Bekele Snr T, Asmamaw Dejenie T
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	crispr cas9 crispr- cas9 technology cancer lung cancer cancer treatment Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/f6c11d6d54ca4c30bd1f78c69060ec0d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f6c11d6d54ca4c30bd1f78c69060ec0d
record_format	dspace
spelling	oai:doaj.org-article:f6c11d6d54ca4c30bd1f78c69060ec0d2021-12-02T14:39:27ZCurrent Applications and Future Perspectives of CRISPR-Cas9 for the Treatment of Lung Cancer1177-5491https://doaj.org/article/f6c11d6d54ca4c30bd1f78c69060ec0d2021-05-01T00:00:00Zhttps://www.dovepress.com/current-applications-and-future-perspectives-of-crispr-cas9-for-the-tr-peer-reviewed-fulltext-article-BTThttps://doaj.org/toc/1177-5491Markeshaw Tiruneh G/Medhin,1 Endeshaw Chekol Abebe,2 Tekeba Sisay,3 Nega Berhane,3 Tesfahun Bekele Snr,1 Tadesse Asmamaw Dejenie1 1Department of Biochemistry, School of Medicine, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia; 2Department of Biochemistry, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia; 3Institute of Biotechnology, College of Natural Science, University of Gondar, Gondar, EthiopiaCorrespondence: Markeshaw Tiruneh G/Medhin Tel +251922712112Email tirunehmarkeshaw1@gmail.comAbstract: Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated proteins are referred to as CRISPR-Cas9. Bacteria and archaea have an adaptive (acquired) immune system. As a result, developing the best single regulated RNA and Cas9 endonuclease proteins and implementing the method in clinical practice would aid in the treatment of diseases of various origins, including lung cancers. This seminar aims to provide an overview of CRISPR-Cas9 technology, as well as current and potential applications and perspectives for the method, as well as its mechanism of action in lung cancer therapy. This technology can be used to treat lung cancer in two different ways. The first approach involves creating single directed RNA and Cas9 proteins and then distributing them to cancer cells using suitable methods. Single directed RNA looks directly at the lung’s mutated epidermal growth factor receptor and makes a complementary match, which is then cleaved with Cas9 protein, slowing cancer progression. The second method is to manipulate the expression of ligand-receptors on immune lymphocytic cells. For example, if the CRISPR-Cas9 system disables the expression of cancer receptors on lymphocytes, it decreases the contact between the tumor cell and its ligand-receptor, thus slowing cancer progression.Keywords: CRISPR, Cas9, CRISPR-Cas9 technology, cancer, lung cancer, cancer treatmentTiruneh G/Medhin MChekol Abebe ESisay TBerhane NBekele Snr TAsmamaw Dejenie TDove Medical Pressarticlecrisprcas9crispr- cas9 technologycancerlung cancercancer treatmentMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol Volume 15, Pp 199-204 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	crispr cas9 crispr- cas9 technology cancer lung cancer cancer treatment Medicine (General) R5-920
spellingShingle	crispr cas9 crispr- cas9 technology cancer lung cancer cancer treatment Medicine (General) R5-920 Tiruneh G/Medhin M Chekol Abebe E Sisay T Berhane N Bekele Snr T Asmamaw Dejenie T Current Applications and Future Perspectives of CRISPR-Cas9 for the Treatment of Lung Cancer
description	Markeshaw Tiruneh G/Medhin,1 Endeshaw Chekol Abebe,2 Tekeba Sisay,3 Nega Berhane,3 Tesfahun Bekele Snr,1 Tadesse Asmamaw Dejenie1 1Department of Biochemistry, School of Medicine, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia; 2Department of Biochemistry, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia; 3Institute of Biotechnology, College of Natural Science, University of Gondar, Gondar, EthiopiaCorrespondence: Markeshaw Tiruneh G/Medhin Tel +251922712112Email tirunehmarkeshaw1@gmail.comAbstract: Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated proteins are referred to as CRISPR-Cas9. Bacteria and archaea have an adaptive (acquired) immune system. As a result, developing the best single regulated RNA and Cas9 endonuclease proteins and implementing the method in clinical practice would aid in the treatment of diseases of various origins, including lung cancers. This seminar aims to provide an overview of CRISPR-Cas9 technology, as well as current and potential applications and perspectives for the method, as well as its mechanism of action in lung cancer therapy. This technology can be used to treat lung cancer in two different ways. The first approach involves creating single directed RNA and Cas9 proteins and then distributing them to cancer cells using suitable methods. Single directed RNA looks directly at the lung’s mutated epidermal growth factor receptor and makes a complementary match, which is then cleaved with Cas9 protein, slowing cancer progression. The second method is to manipulate the expression of ligand-receptors on immune lymphocytic cells. For example, if the CRISPR-Cas9 system disables the expression of cancer receptors on lymphocytes, it decreases the contact between the tumor cell and its ligand-receptor, thus slowing cancer progression.Keywords: CRISPR, Cas9, CRISPR-Cas9 technology, cancer, lung cancer, cancer treatment
format	article
author	Tiruneh G/Medhin M Chekol Abebe E Sisay T Berhane N Bekele Snr T Asmamaw Dejenie T
author_facet	Tiruneh G/Medhin M Chekol Abebe E Sisay T Berhane N Bekele Snr T Asmamaw Dejenie T
author_sort	Tiruneh G/Medhin M
title	Current Applications and Future Perspectives of CRISPR-Cas9 for the Treatment of Lung Cancer
title_short	Current Applications and Future Perspectives of CRISPR-Cas9 for the Treatment of Lung Cancer
title_full	Current Applications and Future Perspectives of CRISPR-Cas9 for the Treatment of Lung Cancer
title_fullStr	Current Applications and Future Perspectives of CRISPR-Cas9 for the Treatment of Lung Cancer
title_full_unstemmed	Current Applications and Future Perspectives of CRISPR-Cas9 for the Treatment of Lung Cancer
title_sort	current applications and future perspectives of crispr-cas9 for the treatment of lung cancer
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/f6c11d6d54ca4c30bd1f78c69060ec0d
work_keys_str_mv	AT tirunehgmedhinm currentapplicationsandfutureperspectivesofcrisprcas9forthetreatmentoflungcancer AT chekolabebee currentapplicationsandfutureperspectivesofcrisprcas9forthetreatmentoflungcancer AT sisayt currentapplicationsandfutureperspectivesofcrisprcas9forthetreatmentoflungcancer AT berhanen currentapplicationsandfutureperspectivesofcrisprcas9forthetreatmentoflungcancer AT bekelesnrt currentapplicationsandfutureperspectivesofcrisprcas9forthetreatmentoflungcancer AT asmamawdejeniet currentapplicationsandfutureperspectivesofcrisprcas9forthetreatmentoflungcancer
_version_	1718390630431850496

Current Applications and Future Perspectives of CRISPR-Cas9 for the Treatment of Lung Cancer

Ejemplares similares